Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Immunotherapy. 2022 Aug;14(12):909-914. doi: 10.2217/imt-2021-0050. Epub 2022 Jul 5.
The paradigm for combined small-cell lung carcinoma (C-SCLC) is according to standard SCLC treatment with poor outcomes. The efficacy of immune checkpoint inhibitor (ICI) monotherapy for pretreated SCLC is still limited. Clinical researches exploring radiotherapy combined with immunotherapy showed promising synergistic effects in several tumors. We report one C-SCLC case after resistant to comprehensive treatment receiving nivolumab combined with radiotherapy achieving clinical complete remission (CCR). The combination module of ICI and radiation could be an option for relapsed C-SCLC, and the prognostic indicators need further research.
小细胞肺癌（SCLC）合并症的范例是根据标准 SCLC 治疗，预后较差。免疫检查点抑制剂（ICI）单药治疗预处理 SCLC 的疗效仍然有限。探索放疗联合免疫治疗的临床研究在几种肿瘤中显示出有希望的协同作用。我们报告了一例对综合治疗耐药的 SCLC 合并症患者，在接受纳武单抗联合放疗后达到临床完全缓解（CCR）。ICI 和放疗的联合治疗方案可能是复发性 SCLC 的一种选择，其预后指标需要进一步研究。
